Sermorelin & Ipamorelin Blend (10mg)

This 10mg blend combines Sermorelin 5mg and Ipamorelin 5mg in a single vial, synthesized and lyophilized in the USA with HPLC-MS verified purity above 99%.

Each vial of Sermorelin & Ipamorelin Blend (10mg) contains a pre-weighed ratio of Sermorelin 5mg, Ipamorelin 5mg in a single lyophilized cake, simplifying multi-peptide research protocols.

Work with Sermorelin & Ipamorelin Blend (10mg) typically combines receptor-binding assays with LC-MS identity confirmation for batch consistency.

Sermorelin & Ipamorelin Blend (10mg) is studied within growth-hormone research for its influence on the somatotropic axis in experimental protocols.

Investigations of Sermorelin & Ipamorelin Blend (10mg) commonly measure secretagogue activity and downstream signaling markers in controlled cell models.

Each vial contains lyophilized peptide at the labeled quantity, and wholesale orders are packed in boxes of ten vials at a single per-vial price.

Quality assurance: every batch is purified by reversed-phase high-performance liquid chromatography and identity-confirmed by mass spectrometry, with purity above 99%. Lot-specific certificates of analysis are available on request. Store lyophilized vials at -20°C, protected from light and moisture; reconstitute with bacteriostatic water immediately before use and avoid repeated freeze-thaw cycles. For in-vitro laboratory research use only — not for human or veterinary use.

Research & Literature

The following peer-reviewed studies and reference documents are commonly consulted by researchers working with Sermorelin & Ipamorelin Blend (10mg). Summaries are provided for orientation only and reflect the cited sources.

Treatment of growth-hormone deficiency with growth-hormone-releasing hormone^[1] — This clinical study evaluated the use of growth-hormone-releasing hormone (GHRH) in the treatment of growth hormone deficiency. The authors assessed growth responses in treated children. The findings supported GHRH as a therapeutic approach for GH-deficient patients, providing a basis for later GHRH-based peptides such as sermorelin. (The Lancet 1987)

Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency^[2] — This review summarized the use of sermorelin, the GHRH 1-29 fragment, in the diagnosis and treatment of children with idiopathic growth hormone deficiency. The authors examined its efficacy in stimulating endogenous GH secretion and supporting growth. The review concluded that sermorelin is a well-tolerated option for evaluating and managing GH deficiency. (BioDrugs 1999)

Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats^[3] — This study tested whether the growth-hormone-releasing peptide ipamorelin could stimulate longitudinal bone growth in rats. The authors examined the effects of ipamorelin administration on bone growth and related IGF-1 responses. The results suggested that ipamorelin promotes skeletal growth through stimulation of the GH-IGF-1 axis, supporting its role in this blend. (Growth Hormone & IGF Research 1999)

Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption^[4] — This study evaluated the pharmacokinetics of ipamorelin and other peptidyl growth hormone secretagogues, with particular attention to nasal absorption. The authors compared systemic exposure after different routes of administration. The findings indicated that ipamorelin has favorable absorption characteristics among the GHRP-class peptides. (Xenobiotica 1999)

References

1. Ross RJM, et al.. "Treatment of growth-hormone deficiency with growth-hormone-releasing hormone." The Lancet. 1987. pubmed.ncbi.nlm.nih.gov/2879138/
2. Prakash A, Goa KL. "Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency." BioDrugs. 1999. pubmed.ncbi.nlm.nih.gov/18031173/
3. Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H. "Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats." Growth Hormone & IGF Research. 1999. pubmed.ncbi.nlm.nih.gov/10373343/
4. Johansen PB, Hansen KT, Andersen JV, Johansen NL. "Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption." Xenobiotica. 1999. pubmed.ncbi.nlm.nih.gov/9879640/

All products are supplied as lyophilized powder for in-vitro laboratory research use only and are not for human or veterinary use.